Dr. Adam Brufsky opens the discussion by introducing the evolving treatment landscape for patients with HR-positive/HER2-negative metastatic breast cancer.

Dr. Adam Brufsky leads a discussion on the evolving role of triplet therapy in HR-positive/HER2-negative metastatic breast cancer, focusing on the clinical implications of the INAVO-120 study and how its findings may influence treatment selection.

Dr. Adam Brufsky leads a discussion on the evolving role of triplet therapy in HR-positive/HER2-negative metastatic breast cancer, focusing on the clinical implications of the INAVO-120 study and how its findings may influence treatment selection.

Dr. Adam Brufsky and the panel discuss the practical implementation of PI3K-directed triplet therapy in patients with HR-positive/HER2-negative metastatic breast cancer, focusing on treatment selection, sequencing considerations, and toxicity management.

Dr. Adam Brufsky and the panel examine treatment decision-making following progression on first-line CDK4/6 inhibitor-based therapy in patients with HR-positive/HER2-negative metastatic breast cancer.

Dr. Adam Brufsky and the panel continue their discussion of treatment sequencing in HR-positive/HER2-negative metastatic breast cancer, focusing on the role of molecular profiling and biomarker-directed therapy following progression on CDK4/6 inhibitor-based treatment.

Dr. Adam Brufsky and the panel transition to a discussion of oral selective estrogen receptor degraders (SERDs) and their evolving role in the management of HR-positive/HER2-negative metastatic breast cancer.

Dr. Adam Brufsky leads a discussion on one of the most debated topics in HR-positive/HER2-negative metastatic breast cancer: the use of oral SERDs and the potential role of molecular monitoring to guide treatment changes before radiographic progression.

Dr. Adam Brufsky and the panel continue their discussion of oral SERDs in HR-positive/HER2-negative metastatic breast cancer, focusing on how emerging clinical data may influence treatment sequencing after progression on CDK4/6 inhibitor-based therapy.

Dr. Adam Brufsky and the panel shift their focus to early-stage HR-positive/HER2-negative breast cancer and discuss emerging endocrine therapy strategies that may influence future treatment paradigms.

Dr. Adam Brufsky and the panel conclude their discussion by examining the increasingly complex treatment landscape for patients with HR-positive/HER2-negative metastatic breast cancer who experience recurrence after receiving modern adjuvant therapies.

Dr. Adam Brufsky and the panel conclude the program by exploring future treatment considerations in HR-positive/HER2-negative metastatic breast cancer, including the expanding number of available oral SERDs and the factors that may influence treatment selection.

Dr. Adam Brufsky concludes the discussion by asking the panel to reflect on the most significant unmet needs in the management of HR-positive/HER2-negative metastatic breast cancer and the future direction of the field.